Genmab agrees $8bn takeover of cancer biotech Merus
Antibody specialist Genmab has continued its shift from out-licensing drugs to developing its own medicines with a deal to buy Merus and its lead drug candidate for head and neck cancer for around $8 billion. Denmark and Netherlands-based Genmab is buying its Nasdaq-listed Dutch rival for $97 per share, nearly 10 times the value of…